AstraZeneca Straddles The Fence On Antibiotics; Is It About To Fall Off?
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.
You may also be interested in...
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.
Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
AstraZeneca Seeking Patient Investors: Pipeline Holds Promise, But Long-Term
AstraZeneca’s mid-stage pipeline includes several interesting assets, particularly in oncology, and the company is determined to accelerate development of key projects under CEO Soriot’s turn-around plan. But even if the R&D team successfully executes on faster development timelines, the reward for investors is years away.